Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO-B) Stock Competitors & Peer Comparison
See (BIO-B) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO-B | $268.55 | +0.00% | 7.2B | 9.65 | $27.84 | N/A |
| ABT | $108.03 | -0.10% | 187.7B | 29.04 | $3.72 | +2.21% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $336.77 | -0.13% | 128.9B | 40.08 | $8.40 | +1.00% |
| MDT | $87.14 | -0.27% | 111.9B | 24.34 | $3.58 | +3.24% |
| BSX | $69.13 | +0.84% | 102.6B | 35.64 | $1.94 | N/A |
| EW | $81.81 | -3.31% | 47.5B | 45.19 | $1.81 | N/A |
| BRKRP | $0.00 | -100.00% | 41.2B | N/A | N/A | +0.59% |
| PHG | $27.79 | -1.68% | 26.7B | 25.98 | $1.07 | +3.18% |
| DXCM | $64.24 | -1.56% | 25.1B | 30.74 | $2.09 | N/A |
Stock Comparison
BIO-B vs ABT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ABT has a market cap of 187.7B. Regarding current trading prices, BIO-B is priced at $268.55, while ABT trades at $108.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ABT's P/E ratio is 29.04. In terms of profitability, BIO-B's ROE is +0.11%, compared to ABT's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ABT's competition here
BIO-B vs BSX-PA Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO-B is priced at $268.55, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO-B's ROE is +0.11%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX-PA's competition here
BIO-B vs SYK Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SYK has a market cap of 128.9B. Regarding current trading prices, BIO-B is priced at $268.55, while SYK trades at $336.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SYK's P/E ratio is 40.08. In terms of profitability, BIO-B's ROE is +0.11%, compared to SYK's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SYK's competition here
BIO-B vs MDT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, MDT has a market cap of 111.9B. Regarding current trading prices, BIO-B is priced at $268.55, while MDT trades at $87.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas MDT's P/E ratio is 24.34. In terms of profitability, BIO-B's ROE is +0.11%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MDT's competition here
BIO-B vs BSX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BSX has a market cap of 102.6B. Regarding current trading prices, BIO-B is priced at $268.55, while BSX trades at $69.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BSX's P/E ratio is 35.64. In terms of profitability, BIO-B's ROE is +0.11%, compared to BSX's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSX's competition here
BIO-B vs EW Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, EW has a market cap of 47.5B. Regarding current trading prices, BIO-B is priced at $268.55, while EW trades at $81.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas EW's P/E ratio is 45.19. In terms of profitability, BIO-B's ROE is +0.11%, compared to EW's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EW's competition here
BIO-B vs BRKRP Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BRKRP has a market cap of 41.2B. Regarding current trading prices, BIO-B is priced at $268.55, while BRKRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BRKRP's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.11%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, Volatility data is not available for a full comparison. BIO-B has daily volatility of 0.97 and BRKRP has daily volatility of N/A.Check BRKRP's competition here
BIO-B vs PHG Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PHG has a market cap of 26.7B. Regarding current trading prices, BIO-B is priced at $268.55, while PHG trades at $27.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PHG's P/E ratio is 25.98. In terms of profitability, BIO-B's ROE is +0.11%, compared to PHG's ROE of +0.08%. Regarding short-term risk, BIO-B is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PHG's competition here
BIO-B vs DXCM Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, DXCM has a market cap of 25.1B. Regarding current trading prices, BIO-B is priced at $268.55, while DXCM trades at $64.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas DXCM's P/E ratio is 30.74. In terms of profitability, BIO-B's ROE is +0.11%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, BIO-B is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check DXCM's competition here
BIO-B vs STE Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, STE has a market cap of 21.1B. Regarding current trading prices, BIO-B is priced at $268.55, while STE trades at $214.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas STE's P/E ratio is 29.89. In terms of profitability, BIO-B's ROE is +0.11%, compared to STE's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check STE's competition here
BIO-B vs ZBH Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ZBH has a market cap of 18.5B. Regarding current trading prices, BIO-B is priced at $268.55, while ZBH trades at $93.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ZBH's P/E ratio is 25.68. In terms of profitability, BIO-B's ROE is +0.11%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ZBH's competition here
BIO-B vs ABMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO-B is priced at $268.55, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO-B's ROE is +0.11%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO-B is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check ABMD's competition here
BIO-B vs PODD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PODD has a market cap of 15.5B. Regarding current trading prices, BIO-B is priced at $268.55, while PODD trades at $219.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PODD's P/E ratio is 62.99. In terms of profitability, BIO-B's ROE is +0.11%, compared to PODD's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PODD's competition here
BIO-B vs SNN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SNN has a market cap of 14.2B. Regarding current trading prices, BIO-B is priced at $268.55, while SNN trades at $32.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SNN's P/E ratio is 22.88. In terms of profitability, BIO-B's ROE is +0.11%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNN's competition here
BIO-B vs PEN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PEN has a market cap of 13.2B. Regarding current trading prices, BIO-B is priced at $268.55, while PEN trades at $336.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PEN's P/E ratio is 74.67. In terms of profitability, BIO-B's ROE is +0.11%, compared to PEN's ROE of +0.13%. Regarding short-term risk, BIO-B is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check PEN's competition here
BIO-B vs SWAV Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $268.55, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO-B's ROE is +0.11%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO-B is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SWAV's competition here
BIO-B vs ALGN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ALGN has a market cap of 11.8B. Regarding current trading prices, BIO-B is priced at $268.55, while ALGN trades at $164.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ALGN's P/E ratio is 29.07. In terms of profitability, BIO-B's ROE is +0.11%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ALGN's competition here
BIO-B vs GMED Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, GMED has a market cap of 11.5B. Regarding current trading prices, BIO-B is priced at $268.55, while GMED trades at $84.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas GMED's P/E ratio is 21.63. In terms of profitability, BIO-B's ROE is +0.11%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GMED's competition here
BIO-B vs BIO Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BIO has a market cap of 7.1B. Regarding current trading prices, BIO-B is priced at $268.55, while BIO trades at $262.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BIO's P/E ratio is 9.36. In terms of profitability, BIO-B's ROE is +0.11%, compared to BIO's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BIO's competition here
BIO-B vs GKOS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, GKOS has a market cap of 5.6B. Regarding current trading prices, BIO-B is priced at $268.55, while GKOS trades at $97.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas GKOS's P/E ratio is -29.56. In terms of profitability, BIO-B's ROE is +0.11%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, BIO-B is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check GKOS's competition here
BIO-B vs BRKR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BRKR has a market cap of 5.1B. Regarding current trading prices, BIO-B is priced at $268.55, while BRKR trades at $33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BRKR's P/E ratio is -225.00. In terms of profitability, BIO-B's ROE is +0.11%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, BIO-B is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BRKR's competition here
BIO-B vs NARI Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $268.55, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO-B's ROE is +0.11%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO-B is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check NARI's competition here
BIO-B vs TMDX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, TMDX has a market cap of 4.2B. Regarding current trading prices, BIO-B is priced at $268.55, while TMDX trades at $123.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas TMDX's P/E ratio is 25.41. In terms of profitability, BIO-B's ROE is +0.11%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, BIO-B is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TMDX's competition here
BIO-B vs IRTC Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, BIO-B is priced at $268.55, while IRTC trades at $113.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas IRTC's P/E ratio is -81.29. In terms of profitability, BIO-B's ROE is +0.11%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, BIO-B is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRTC's competition here
BIO-B vs AXNX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO-B is priced at $268.55, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO-B's ROE is +0.11%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO-B is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check AXNX's competition here
BIO-B vs LIVN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, LIVN has a market cap of 3.2B. Regarding current trading prices, BIO-B is priced at $268.55, while LIVN trades at $58.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas LIVN's P/E ratio is -13.14. In terms of profitability, BIO-B's ROE is +0.11%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, BIO-B is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LIVN's competition here
BIO-B vs ITGR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ITGR has a market cap of 2.9B. Regarding current trading prices, BIO-B is priced at $268.55, while ITGR trades at $82.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ITGR's P/E ratio is 28.72. In terms of profitability, BIO-B's ROE is +0.11%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ITGR's competition here
BIO-B vs NUVA Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $268.55, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO-B's ROE is +0.11%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NUVA's competition here
BIO-B vs PMI Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PMI has a market cap of 2B. Regarding current trading prices, BIO-B is priced at $268.55, while PMI trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PMI's P/E ratio is -2.91. In terms of profitability, BIO-B's ROE is +0.11%, compared to PMI's ROE of +1.64%. Regarding short-term risk, BIO-B is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PMI's competition here
BIO-B vs ATEC Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, BIO-B is priced at $268.55, while ATEC trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ATEC's P/E ratio is -12.79. In terms of profitability, BIO-B's ROE is +0.11%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, BIO-B is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ATEC's competition here
BIO-B vs ESTA Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, BIO-B is priced at $268.55, while ESTA trades at $63.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ESTA's P/E ratio is -36.83. In terms of profitability, BIO-B's ROE is +0.11%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, BIO-B is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ESTA's competition here
BIO-B vs AORT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, BIO-B is priced at $268.55, while AORT trades at $36.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AORT's P/E ratio is 173.38. In terms of profitability, BIO-B's ROE is +0.11%, compared to AORT's ROE of +0.02%. Regarding short-term risk, BIO-B is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AORT's competition here
BIO-B vs INSP Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, BIO-B is priced at $268.55, while INSP trades at $58.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas INSP's P/E ratio is 11.99. In terms of profitability, BIO-B's ROE is +0.11%, compared to INSP's ROE of +0.21%. Regarding short-term risk, BIO-B is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INSP's competition here
BIO-B vs AXGN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AXGN has a market cap of 1.7B. Regarding current trading prices, BIO-B is priced at $268.55, while AXGN trades at $32.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AXGN's P/E ratio is -95.12. In terms of profitability, BIO-B's ROE is +0.11%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AXGN's competition here
BIO-B vs UFPT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, UFPT has a market cap of 1.6B. Regarding current trading prices, BIO-B is priced at $268.55, while UFPT trades at $203.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas UFPT's P/E ratio is 23.33. In terms of profitability, BIO-B's ROE is +0.11%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check UFPT's competition here
BIO-B vs PRCT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, BIO-B is priced at $268.55, while PRCT trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PRCT's P/E ratio is -15.77. In terms of profitability, BIO-B's ROE is +0.11%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, BIO-B is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PRCT's competition here
BIO-B vs TNDM Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, BIO-B is priced at $268.55, while TNDM trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas TNDM's P/E ratio is -7.12. In terms of profitability, BIO-B's ROE is +0.11%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, BIO-B is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TNDM's competition here
BIO-B vs AHCO Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $268.55, while AHCO trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AHCO's P/E ratio is -20.37. In terms of profitability, BIO-B's ROE is +0.11%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, BIO-B is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AHCO's competition here
BIO-B vs HSKA Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $268.55, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO-B's ROE is +0.11%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO-B is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check HSKA's competition here
BIO-B vs IRMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $268.55, while IRMD trades at $99.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas IRMD's P/E ratio is 56.01. In terms of profitability, BIO-B's ROE is +0.11%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BIO-B is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IRMD's competition here
BIO-B vs CNMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $268.55, while CNMD trades at $37.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CNMD's P/E ratio is 24.71. In terms of profitability, BIO-B's ROE is +0.11%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CNMD's competition here
BIO-B vs LMRI Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $268.55, while LMRI trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas LMRI's P/E ratio is -26.50. In terms of profitability, BIO-B's ROE is +0.11%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, BIO-B is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LMRI's competition here
BIO-B vs SILK Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $268.55, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO-B's ROE is +0.11%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO-B is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SILK's competition here
BIO-B vs FNA Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $268.55, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO-B's ROE is +0.11%, compared to FNA's ROE of -0.17%. Regarding short-term risk, BIO-B is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check FNA's competition here
BIO-B vs BFLY Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BFLY has a market cap of 970.2M. Regarding current trading prices, BIO-B is priced at $268.55, while BFLY trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BFLY's P/E ratio is -12.29. In terms of profitability, BIO-B's ROE is +0.11%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY's competition here
BIO-B vs SSII Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SSII has a market cap of 866.8M. Regarding current trading prices, BIO-B is priced at $268.55, while SSII trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SSII's P/E ratio is -74.33. In terms of profitability, BIO-B's ROE is +0.11%, compared to SSII's ROE of -0.30%. Regarding short-term risk, BIO-B is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SSII's competition here
BIO-B vs INMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, INMD has a market cap of 857.9M. Regarding current trading prices, BIO-B is priced at $268.55, while INMD trades at $13.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas INMD's P/E ratio is 9.47. In terms of profitability, BIO-B's ROE is +0.11%, compared to INMD's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check INMD's competition here
BIO-B vs CSII Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO-B is priced at $268.55, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO-B's ROE is +0.11%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO-B is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check CSII's competition here
BIO-B vs CRY Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BIO-B is priced at $268.55, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CRY's P/E ratio is 425.71. In terms of profitability, BIO-B's ROE is +0.11%, compared to CRY's ROE of +0.02%. Regarding short-term risk, BIO-B is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CRY's competition here
BIO-B vs IART Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, IART has a market cap of 720.1M. Regarding current trading prices, BIO-B is priced at $268.55, while IART trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas IART's P/E ratio is -1.37. In terms of profitability, BIO-B's ROE is +0.11%, compared to IART's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check IART's competition here
BIO-B vs CBLL Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CBLL has a market cap of 696M. Regarding current trading prices, BIO-B is priced at $268.55, while CBLL trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CBLL's P/E ratio is -12.66. In terms of profitability, BIO-B's ROE is +0.11%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, BIO-B is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CBLL's competition here
BIO-B vs AVNS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AVNS has a market cap of 637.6M. Regarding current trading prices, BIO-B is priced at $268.55, while AVNS trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AVNS's P/E ratio is -8.73. In terms of profitability, BIO-B's ROE is +0.11%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO-B is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AVNS's competition here
BIO-B vs SRDX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO-B is priced at $268.55, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO-B's ROE is +0.11%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, BIO-B is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SRDX's competition here
BIO-B vs TCMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, TCMD has a market cap of 604.3M. Regarding current trading prices, BIO-B is priced at $268.55, while TCMD trades at $26.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas TCMD's P/E ratio is 32.84. In terms of profitability, BIO-B's ROE is +0.11%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, BIO-B is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TCMD's competition here
BIO-B vs APEN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO-B is priced at $268.55, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO-B's ROE is +0.11%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO-B is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check APEN's competition here
BIO-B vs BVS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BVS has a market cap of 577.3M. Regarding current trading prices, BIO-B is priced at $268.55, while BVS trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BVS's P/E ratio is 53.87. In terms of profitability, BIO-B's ROE is +0.11%, compared to BVS's ROE of +0.14%. Regarding short-term risk, BIO-B is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BVS's competition here
BIO-B vs SIBN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SIBN has a market cap of 576.4M. Regarding current trading prices, BIO-B is priced at $268.55, while SIBN trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SIBN's P/E ratio is -29.66. In terms of profitability, BIO-B's ROE is +0.11%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, BIO-B is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SIBN's competition here
BIO-B vs BWAY Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BWAY has a market cap of 537.7M. Regarding current trading prices, BIO-B is priced at $268.55, while BWAY trades at $13.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BWAY's P/E ratio is 85.69. In terms of profitability, BIO-B's ROE is +0.11%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BWAY's competition here
BIO-B vs ZIMV Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO-B is priced at $268.55, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO-B's ROE is +0.11%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, BIO-B is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check ZIMV's competition here
BIO-B vs CTKB Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CTKB has a market cap of 515.5M. Regarding current trading prices, BIO-B is priced at $268.55, while CTKB trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CTKB's P/E ratio is -7.71. In terms of profitability, BIO-B's ROE is +0.11%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CTKB's competition here
BIO-B vs NPCE Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, NPCE has a market cap of 474.4M. Regarding current trading prices, BIO-B is priced at $268.55, while NPCE trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas NPCE's P/E ratio is -20.72. In terms of profitability, BIO-B's ROE is +0.11%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, BIO-B is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NPCE's competition here
BIO-B vs OFIX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, OFIX has a market cap of 469.7M. Regarding current trading prices, BIO-B is priced at $268.55, while OFIX trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas OFIX's P/E ratio is -5.02. In terms of profitability, BIO-B's ROE is +0.11%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, BIO-B is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check OFIX's competition here
BIO-B vs VREX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, VREX has a market cap of 453.1M. Regarding current trading prices, BIO-B is priced at $268.55, while VREX trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas VREX's P/E ratio is -6.55. In terms of profitability, BIO-B's ROE is +0.11%, compared to VREX's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VREX's competition here
BIO-B vs KIDS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, KIDS has a market cap of 437.6M. Regarding current trading prices, BIO-B is priced at $268.55, while KIDS trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas KIDS's P/E ratio is -10.24. In terms of profitability, BIO-B's ROE is +0.11%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BIO-B is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check KIDS's competition here
BIO-B vs PACB Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PACB has a market cap of 401.7M. Regarding current trading prices, BIO-B is priced at $268.55, while PACB trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PACB's P/E ratio is -0.74. In terms of profitability, BIO-B's ROE is +0.11%, compared to PACB's ROE of -11.23%. Regarding short-term risk, BIO-B is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PACB's competition here
BIO-B vs CATX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CATX has a market cap of 370.9M. Regarding current trading prices, BIO-B is priced at $268.55, while CATX trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CATX's P/E ratio is -3.30. In terms of profitability, BIO-B's ROE is +0.11%, compared to CATX's ROE of -0.39%. Regarding short-term risk, BIO-B is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CATX's competition here
BIO-B vs LAB Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, LAB has a market cap of 358.6M. Regarding current trading prices, BIO-B is priced at $268.55, while LAB trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas LAB's P/E ratio is -6.22. In terms of profitability, BIO-B's ROE is +0.11%, compared to LAB's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LAB's competition here
BIO-B vs VMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, VMD has a market cap of 356.8M. Regarding current trading prices, BIO-B is priced at $268.55, while VMD trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas VMD's P/E ratio is 27.06. In terms of profitability, BIO-B's ROE is +0.11%, compared to VMD's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check VMD's competition here
BIO-B vs DCTH Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, DCTH has a market cap of 328.4M. Regarding current trading prices, BIO-B is priced at $268.55, while DCTH trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas DCTH's P/E ratio is 135.00. In terms of profitability, BIO-B's ROE is +0.11%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check DCTH's competition here
BIO-B vs CERS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CERS has a market cap of 324.8M. Regarding current trading prices, BIO-B is priced at $268.55, while CERS trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CERS's P/E ratio is -21.12. In terms of profitability, BIO-B's ROE is +0.11%, compared to CERS's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CERS's competition here
BIO-B vs CLPT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CLPT has a market cap of 321M. Regarding current trading prices, BIO-B is priced at $268.55, while CLPT trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CLPT's P/E ratio is -13.00. In terms of profitability, BIO-B's ROE is +0.11%, compared to CLPT's ROE of -1.14%. Regarding short-term risk, BIO-B is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CLPT's competition here
BIO-B vs SMLR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO-B is priced at $268.55, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO-B's ROE is +0.11%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, BIO-B is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check SMLR's competition here
BIO-B vs RXST Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, RXST has a market cap of 302.5M. Regarding current trading prices, BIO-B is priced at $268.55, while RXST trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas RXST's P/E ratio is -7.72. In terms of profitability, BIO-B's ROE is +0.11%, compared to RXST's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RXST's competition here
BIO-B vs MGRM Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO-B is priced at $268.55, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas MGRM's P/E ratio is -11.11. In terms of profitability, BIO-B's ROE is +0.11%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, BIO-B is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check MGRM's competition here
BIO-B vs SENS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SENS has a market cap of 235.6M. Regarding current trading prices, BIO-B is priced at $268.55, while SENS trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SENS's P/E ratio is -3.40. In terms of profitability, BIO-B's ROE is +0.11%, compared to SENS's ROE of -1.04%. Regarding short-term risk, BIO-B is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SENS's competition here
BIO-B vs AVR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, AVR has a market cap of 227.7M. Regarding current trading prices, BIO-B is priced at $268.55, while AVR trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas AVR's P/E ratio is -2.43. In terms of profitability, BIO-B's ROE is +0.11%, compared to AVR's ROE of -5.28%. Regarding short-term risk, BIO-B is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check AVR's competition here
BIO-B vs NVRO Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO-B is priced at $268.55, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO-B's ROE is +0.11%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, BIO-B is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check NVRO's competition here
BIO-B vs QTRX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, QTRX has a market cap of 221.6M. Regarding current trading prices, BIO-B is priced at $268.55, while QTRX trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas QTRX's P/E ratio is -1.88. In terms of profitability, BIO-B's ROE is +0.11%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check QTRX's competition here
BIO-B vs MASS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, MASS has a market cap of 219.7M. Regarding current trading prices, BIO-B is priced at $268.55, while MASS trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas MASS's P/E ratio is -6.53. In terms of profitability, BIO-B's ROE is +0.11%, compared to MASS's ROE of +0.13%. Regarding short-term risk, BIO-B is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MASS's competition here
BIO-B vs EYES Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BIO-B is priced at $268.55, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas EYES's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.11%, compared to EYES's ROE of -4.16%. Regarding short-term risk, BIO-B is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EYES's competition here
BIO-B vs ANIK Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ANIK has a market cap of 204.8M. Regarding current trading prices, BIO-B is priced at $268.55, while ANIK trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ANIK's P/E ratio is -20.29. In terms of profitability, BIO-B's ROE is +0.11%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, BIO-B is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ANIK's competition here
BIO-B vs SGHT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SGHT has a market cap of 198.2M. Regarding current trading prices, BIO-B is priced at $268.55, while SGHT trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SGHT's P/E ratio is -4.96. In terms of profitability, BIO-B's ROE is +0.11%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, BIO-B is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SGHT's competition here
BIO-B vs CVRX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, CVRX has a market cap of 198.1M. Regarding current trading prices, BIO-B is priced at $268.55, while CVRX trades at $7.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas CVRX's P/E ratio is -3.52. In terms of profitability, BIO-B's ROE is +0.11%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, BIO-B is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check CVRX's competition here
BIO-B vs ELMD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, ELMD has a market cap of 195.7M. Regarding current trading prices, BIO-B is priced at $268.55, while ELMD trades at $23.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas ELMD's P/E ratio is 22.78. In terms of profitability, BIO-B's ROE is +0.11%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, BIO-B is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check ELMD's competition here
BIO-B vs BSGM Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO-B is priced at $268.55, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO-B's ROE is +0.11%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, BIO-B is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check BSGM's competition here
BIO-B vs SNWV Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, SNWV has a market cap of 184.5M. Regarding current trading prices, BIO-B is priced at $268.55, while SNWV trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas SNWV's P/E ratio is -29.47. In terms of profitability, BIO-B's ROE is +0.11%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, BIO-B is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check SNWV's competition here
BIO-B vs MDGS Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO-B is priced at $268.55, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO-B's ROE is +0.11%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check MDGS's competition here
BIO-B vs PROF Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, PROF has a market cap of 166.7M. Regarding current trading prices, BIO-B is priced at $268.55, while PROF trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas PROF's P/E ratio is -4.05. In terms of profitability, BIO-B's ROE is +0.11%, compared to PROF's ROE of +0.79%. Regarding short-term risk, BIO-B is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check PROF's competition here
BIO-B vs INGN Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, INGN has a market cap of 165M. Regarding current trading prices, BIO-B is priced at $268.55, while INGN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas INGN's P/E ratio is -7.05. In terms of profitability, BIO-B's ROE is +0.11%, compared to INGN's ROE of -0.12%. Regarding short-term risk, Volatility data is not available for a full comparison. BIO-B has daily volatility of 0.97 and INGN has daily volatility of N/A.Check INGN's competition here
BIO-B vs QTI Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, QTI has a market cap of 162.7M. Regarding current trading prices, BIO-B is priced at $268.55, while QTI trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas QTI's P/E ratio is -2.98. In terms of profitability, BIO-B's ROE is +0.11%, compared to QTI's ROE of +1.72%. Regarding short-term risk, BIO-B is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check QTI's competition here
BIO-B vs QIPT Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO-B is priced at $268.55, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO-B's ROE is +0.11%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BIO-B is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check QIPT's competition here
BIO-B vs NNOX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, NNOX has a market cap of 161M. Regarding current trading prices, BIO-B is priced at $268.55, while NNOX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas NNOX's P/E ratio is -2.87. In terms of profitability, BIO-B's ROE is +0.11%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, BIO-B is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check NNOX's competition here
BIO-B vs TLSI Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, TLSI has a market cap of 154.7M. Regarding current trading prices, BIO-B is priced at $268.55, while TLSI trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas TLSI's P/E ratio is -1.97. In terms of profitability, BIO-B's ROE is +0.11%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, BIO-B is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check TLSI's competition here
BIO-B vs APYX Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, APYX has a market cap of 148.9M. Regarding current trading prices, BIO-B is priced at $268.55, while APYX trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas APYX's P/E ratio is -10.08. In terms of profitability, BIO-B's ROE is +0.11%, compared to APYX's ROE of -1.18%. Regarding short-term risk, BIO-B is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check APYX's competition here
BIO-B vs EDAP Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, EDAP has a market cap of 146.6M. Regarding current trading prices, BIO-B is priced at $268.55, while EDAP trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas EDAP's P/E ratio is -7.00. In terms of profitability, BIO-B's ROE is +0.11%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, BIO-B is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check EDAP's competition here
BIO-B vs LUCD Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, LUCD has a market cap of 139.4M. Regarding current trading prices, BIO-B is priced at $268.55, while LUCD trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas LUCD's P/E ratio is -1.78. In terms of profitability, BIO-B's ROE is +0.11%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, BIO-B is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LUCD's competition here
BIO-B vs RPID Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, RPID has a market cap of 125.4M. Regarding current trading prices, BIO-B is priced at $268.55, while RPID trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas RPID's P/E ratio is -2.83. In terms of profitability, BIO-B's ROE is +0.11%, compared to RPID's ROE of -0.95%. Regarding short-term risk, BIO-B is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check RPID's competition here
BIO-B vs LNSR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, LNSR has a market cap of 117.7M. Regarding current trading prices, BIO-B is priced at $268.55, while LNSR trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas LNSR's P/E ratio is -2.25. In terms of profitability, BIO-B's ROE is +0.11%, compared to LNSR's ROE of +5.33%. Regarding short-term risk, BIO-B is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for BIO-B.Check LNSR's competition here
BIO-B vs FONR Comparison March 2026
BIO-B plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 7.2B. In comparison, FONR has a market cap of 113.5M. Regarding current trading prices, BIO-B is priced at $268.55, while FONR trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of 9.65, whereas FONR's P/E ratio is 15.98. In terms of profitability, BIO-B's ROE is +0.11%, compared to FONR's ROE of +0.04%. Regarding short-term risk, BIO-B is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO-B.Check FONR's competition here